Systemic Thrombolysis in Acute Stroke After Protamine-Reversal of Anticoagulation with Low-Molecular-Weight Heparin
Author | Daniel Bereczki Jr | en |
Author | Zoltan Simony | en |
Author | Zoltan Szakacs | en |
Author | Geza Szilagyi | en |
Issued Date | 2016-10-01 | en |
Abstract | Introduction: Intravenous thrombolysis may be withheld due to current exclusion criteria even if the patient arrives at hospital in time. However, under certain circumstances, some of these contraindications could be eliminated. Case Presentation: We report a systemic thrombolysis after reversal of anticoagulation with protamine sulfate in an acute stroke patient with suspected subacute non-ST-segment elevation myocardial infarction (NSTEMI) receiving full-dose low-molecular-weight heparin (LMWH). Conclusions: Considering the fact that only less than 10% of all acute strokes are eligible for intravenous thrombolysis, in particular circumstances and weighing a risk-benefit ratio, elimination of certain exclusion criteria could be a reasonable method to decrease the number of patients who currently fail to receive adequate treatment. | en |
DOI | https://doi.org/10.5812/archneurosci.35202 | en |
Keyword | Thrombolytic Therapy | en |
Keyword | Stroke | en |
Keyword | Low-Molecular-Weight Heparin | en |
Keyword | Protamine Sulfate | en |
Publisher | Brieflands | en |
Title | Systemic Thrombolysis in Acute Stroke After Protamine-Reversal of Anticoagulation with Low-Molecular-Weight Heparin | en |
Type | Case Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 20585-pdf.pdf
- Size:
- 69.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF